Takara Bio Inc. (JP:4974)
:4974
Want to see JP:4974 full AI Analyst Report?
4974 Stock Chart & Stats
¥786.00
¥1.00(0.10%)
At close: 4:00 PM EST
¥786.00
¥1.00(0.10%)
Day’s Range― - ―
52-Week Range¥752.00 - ¥1,150.00
Previous CloseN/A
Volume153.20K
Average Volume (3M)357.12K
Market Cap
¥137.51B
Enterprise Value¥127.68B
Total Cash (Recent Filing)¥19.83B
Total Debt (Recent Filing)¥10.00B
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.18%
Share Statistics
EPS (TTM)-22.49
Shares Outstanding120,415,600
10 Day Avg. Volume362,320
30 Day Avg. Volume357,120
Financial Highlights & Ratios
PEG Ratio-3.23
Price to Book (P/B)0.86
Price to Sales (P/S)2.21
P/FCF Ratio-24.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)¥43.61B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Workflow StickinessTakara Bio's core sales derive from consumables and reagents that are consumed per experiment and embedded in lab protocols. This creates durable repeat revenue, high switching costs from revalidation, and steady demand as labs maintain validated workflows, supporting long-term revenue visibility.
Conservative Balance Sheet / Low LeverageThe company's low debt position provides financial flexibility to fund R&D, contract services, or bridge cash shortfalls. With limited leverage, Takara can endure cyclical revenue swings or negative free cash flow longer without forcing distress sales or immediate refinancing, preserving strategic optionality.
Solid Gross Margins And Top-line GrowthA ~55% gross margin across reagent and instrument sales indicates durable product-level profitability and pricing power in genomics workflows. Combined with reported revenue growth, this supports margin sustainability if cost structure is managed and demand for genomic and cell/gene tools continues to expand.
Bears Say
Deeply Negative Free Cash FlowPersistent negative free cash flow of ~-¥8.4B signals heavy investment, capex, or working-capital strain. This reduces the firm's ability to self-fund operations and R&D, may force cash reserves draws or external financing, and undermines capital allocation flexibility over the medium term.
Swing To Operating And Net LossesThe move from modest profitability to a sizable net loss erodes earnings power and returns on capital. Sustained operating losses increase uncertainty about sustainable margins, constrain reinvestment in products and services, and elevate execution risk while the company tries to restore profitability.
Demand Cyclicality Tied To Research FundingSales closely track academic and biopharma R&D activity, making revenues sensitive to funding cycles and program timing. This structural cyclicality can amplify revenue volatility, complicate capacity planning, and pressure margins when macro or sector R&D spending weakens, especially amid current losses.
Takara Bio Inc. News
4974 FAQ
What was Takara Bio Inc.’s price range in the past 12 months?
Takara Bio Inc. lowest stock price was ¥752.00 and its highest was ¥1150.00 in the past 12 months.
What is Takara Bio Inc.’s market cap?
Takara Bio Inc.’s market cap is ¥137.51B.
When is Takara Bio Inc.’s upcoming earnings report date?
Takara Bio Inc.’s upcoming earnings report date is May 13, 2026 which is in 23 days.
How were Takara Bio Inc.’s earnings last quarter?
Takara Bio Inc. released its earnings results on Feb 13, 2026. The company reported -¥22.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.49.
Is Takara Bio Inc. overvalued?
According to Wall Street analysts Takara Bio Inc.’s price is currently Overvalued.
Does Takara Bio Inc. pay dividends?
Takara Bio Inc. pays a Annually dividend of ¥17 which represents an annual dividend yield of 2.18%. See more information on Takara Bio Inc. dividends here
What is Takara Bio Inc.’s EPS estimate?
Takara Bio Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Takara Bio Inc. have?
Takara Bio Inc. has 120,415,600 shares outstanding.
What happened to Takara Bio Inc.’s price movement after its last earnings report?
Takara Bio Inc. reported an EPS of -¥22.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Takara Bio Inc.?
Currently, no hedge funds are holding shares in JP:4974
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---